			Home About us Contact

neu + oncogene)

Distribution by Scientific Domains

Medical Sciences	75%

Selected Abstracts

Prognostic and predictive value of HER2/neu oncogene in breast cancer

MICROSCOPY RESEARCH AND TECHNIQUE, Issue 2 2002
Shahla Masood
Abstract Assessment of HER2/neu oncogene has been used as both a prognostic and predictive marker for breast cancer. However, the choice of the best method to assess the status of HER2/neu oncogene in breast cancer tissue remains controversial. A variety of techniques are available to detect HER2/neu gene amplification and overexpression. Tissue-based detection methods by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) offers a clear advantage over other approaches. FISH is a costly and relatively difficult assay and yet appears to be a better predictor of response to Herceptin® (Trastuzumab) therapy and patient outcome. IHC is less expensive and is easier to perform; however, it suffers from a high rate of false negativity and positivity as well as inter-observer variability among pathologists. Suggestions have been made to use IHC as a screening procedure followed by confirmation by FISH in selected cases. Considering the importance of an accurate assessment of HER2/neu oncogene in selecting therapy, a better alternative may be to use FISH as the primary testing for HER2/neu oncogene. Herceptin® therapy is associated with several side effects and is expensive. Thus, in the long term, it may be more cost-effective to use the FISH procedure and reduce the possibility of under-treatment or over-treatment of breast cancer patients. In addition, assessment of HER2/neu oncogene on every newly diagnosed early breast carcinoma may not be necessary. Metastatic lesions, when they occur, can be sampled by fine needle aspiration biopsy or core needle biopsy for assessment of HER2/Neu status. Microsc. Res. Tech. 59:102,108, 2002. © 2002 Wiley-Liss, Inc. [source]

Molecular Imaging of Cancer Cells Using Plasmon-Resonant-Enhanced Third-Harmonic-Generation in Silver Nanoparticles,

ADVANCED MATERIALS, Issue 24 2007
S.-P. Tai
We demonstrate molecule-specific third-harmonic-generation (THG) microscopy by using silver nanoparticles as THG contrast agents. Through matching surface plasmon wavelength to THG wavelength, strong contrast can be provided by silver nanoparticles under THG microscopy. By conjugating anti-her2 antibodies with silver nanoparticles, the expression of the Her2/neu oncogene in the cancer cell membranes is successfully imaged under THG modality for the first time. [source]

Aggressive progression of breast cancer with microscopic pulmonary emboli possessing a stem cell-like phenotype independent of its origin

PATHOLOGY INTERNATIONAL, Issue 3 2010
Hideya Kawasaki
Microscopic pulmonary tumor embolism is difficult to diagnose. Herein is presented the case of a patient who suffered from acute dyspnea and breast cancer on the right side. Two weeks after the breast cancer diagnosis the patient began to experience dyspnea. After 2 weeks of dyspnea, the patient died without an accurate diagnosis of dyspnea. Autopsy indicated massive microscopic pulmonary emboli of the breast cancer. Immunohistochemistry showed that most of the cancer cells in the primary site were negative for estrogen receptors, progesterone receptors Her2/neu oncogene (triple negative), and stem cell-like markers (OCT3/4, NANOG2, CD44, CD24, aldehyde dehydrogenase 1 (ALDH1)). The breast cancer cells in the lung (the metastasized site), however, were triple negative, but were enriched in stem cell-like markers (OCT3/4+, NANOG2+, CD44+/CD24,/low, ALDH1+). This is a significant case report indicating that vascular emboli themselves contain the essential molecular signature of ,stemness' independent of the origin. [source]